Mesenchymal Stem Cell-Derived Exosomes as a Treatment Option for Osteoarthritis.
Anupama VadhanTanvi GuptaWen-Li HsuPublished in: International journal of molecular sciences (2024)
Osteoarthritis (OA) is a leading cause of pain and disability worldwide in elderly people. There is a critical need to develop novel therapeutic strategies that can effectively manage pain and disability to improve the quality of life for older people. Mesenchymal stem cells (MSCs) have emerged as a promising cell-based therapy for age-related disorders due to their multilineage differentiation and strong paracrine effects. Notably, MSC-derived exosomes (MSC-Exos) have gained significant attention because they can recapitulate MSCs into therapeutic benefits without causing any associated risks compared with direct cell transplantation. These exosomes help in the transport of bioactive molecules such as proteins, lipids, and nucleic acids, which can influence various cellular processes related to tissue repair, regeneration, and immune regulation. In this review, we have provided an overview of MSC-Exos as a considerable treatment option for osteoarthritis. This review will go over the underlying mechanisms by which MSC-Exos may alleviate the pathological hallmarks of OA, such as cartilage degradation, synovial inflammation, and subchondral bone changes. Furthermore, we have summarized the current preclinical evidence and highlighted promising results from in vitro and in vivo studies, as well as progress in clinical trials using MSC-Exos to treat OA.
Keyphrases
- drug induced
- mesenchymal stem cells
- cell therapy
- umbilical cord
- knee osteoarthritis
- bone marrow
- clinical trial
- stem cells
- rheumatoid arthritis
- chronic pain
- multiple sclerosis
- single cell
- pain management
- randomized controlled trial
- risk assessment
- human health
- combination therapy
- phase ii
- bone regeneration
- double blind